|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In the "CKP" mouse pancreatic ductal adenocarcinoma (PDAC) model driven by mutant K-Ras, Ctbp2 haploinsufficiency prolonged survival, abrogated peritoneal metastasis, and caused dramatic downregulation of c-Myc, a known critical dependency for TIC activity and tumor progression in PDAC.
|
31586042 |
2019 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In summary, the present studies revealed that the loss of CtBP2 constrained distant metastasis through the JAK1/Stat3 pathway in OS, suggesting that targeting CtBP2 may be a practical anti-tumor approach to prevent OS tumor progression.
|
31214864 |
2019 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
C-terminal binding protein‑2 (CtBP2) is a transcriptional co-repressor that is associated with tumorigenesis and tumor progression.
|
29658564 |
2018 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, silencing of CtBP2 markedly increased the apoptosis of PCa cells in vitro, and decreased the expression of IL-8, AT2R, CCND1 and MMP9 which are associated with cancer progression.
|
28677795 |
2017 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
|
24332637 |
2014 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
C-terminal binding protein-2 (CtBP2) is a CtBP-family member which plays a significant role in tumor initiation, progression and response to therapy.
|
24835310 |
2014 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in vitro.
|
28179207 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CtBP2 was demonstrated to modulate cell migration and invasion via JAK1/Stat3 signaling pathway in fetal osteoblast cells.
|
31214864 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Meanwhile, CTBP2 silencing can rescued the phenotype changes induced by miR-338-5p inhibitor on cell proliferation and invasion in glioma.
|
28826173 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CTBP2 restoration overturned cell viability and invasion suppression mediated by NEAT1 knockdown or miR-129 overexpression.
|
29147064 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CtBP2 induced epithelial-to-mesenchymal transition (EMT) and repressed PTEN to increase proliferation rate, migration, and invasion in GC cells.
|
28404932 |
2017 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CtBP2 is overexpressed in GC and may accelerate GC tumorigenesis and metastasis, which could represent an independent prognostic marker and promising therapeutic target for GC.
|
28404932 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Collectively, all results suggested that CtBP2 might contribute to the progression of ESCC through a negative transcriptional regulation of p16(INK4A).
|
23255392 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
LncRNA NEAT1 Regulates Cell Viability and Invasion in Esophageal Squamous Cell Carcinoma through the miR-129/CTBP2 Axis.
|
29147064 |
2017 |
|
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results indicated that CCNH/CDK7-CtBP2 axis may augment ESCC cell migration, and targeting the interaction of both may provide a novel therapeutic target of ESCC.
|
25820824 |
2015 |
|
Sensory denervation disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Using a combination of histological and functional approaches, we demonstrated four key findings: (1) selective synaptic deafferentation is sufficient to generate acute vestibular syndrome with characteristics similar to those reported in patients; (2) the reduction of the vestibulo-ocular reflex and posturo-locomotor deficits mainly depends on spared synapses; (3) damaged primary vestibular synapses can be repaired over the days and weeks following deafferentation; and (4) the synaptic repair process occurs through the re-expression and re-pairing of synaptic proteins such as CtBP2 and SHANK-1.
|
31213478 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, for the first time, we reported that CtBP2 expression, along with CCNH/CDK7, was higher in ESCC tissues with lymph node metastases than in those without lymph node metastases.
|
25820824 |
2015 |
|
Respiratory Tract Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
CXCL6, CXCL8, KIT and CTBP2 were highlighted as candidate genes that might play important roles in determining resistance/susceptibility to swine EP-like respiratory disease.
|
27615547 |
2017 |
|
Respiration Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
CXCL6, CXCL8, KIT and CTBP2 were highlighted as candidate genes that might play important roles in determining resistance/susceptibility to swine EP-like respiratory disease.
|
27615547 |
2017 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
These results highlight the association between CtBP2 and angiogenesis in PCa and indicate that CtBP2 may be a potential therapeutic target for PCa.
|
28677795 |
2017 |
|
Prostate carcinoma
|
0.160 |
Biomarker
|
disease |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |